Lauren P. Giesler

Lauren P. Giesler

Auto-generated profile, based on publicly available information

Lauren P. Giesler

Department of Neuroscience, School of Translational Medicine, Monash University, Victoria, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2023 in Neurology
Verified
Journal Article
Open access
PDF file
JRJonathan Reyes
Jonathan Reyes
GSGershon Spitz
Gershon Spitz
BMBrendan P. Major
Brendan P. Major
WOWilliam T. O'Brien
William T. O'Brien
LGLauren P. Giesler
Lauren P. Giesler
SMStuart J. McDonald
Stuart J. McDonald
Background and Objectives Blood biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) have recently been Food and Drug Administration approved as predictors of intracranial lesions on CT after mild traumatic brain injury (mTBI). However, most cases with mTBI are CT negative, and no biomarkers are approved to assist diagnosis in these individuals. In this study, we aimed to determine the optimal combination of blood biomarkers to assist mTBI diagnosis in otherwise healthy adults younger than 50 years presenting to an emergency department within 6 hours of injury. To further understand the utility of biomarkers, we assessed how biological sex, presence or absence of loss of consciousness and/or post-traumatic amnesia (LOC/PTA), and delayed presentation affected classification performance. Methods Blood samples, symptom questionnaires, and cognitive tests were prospectively conducted for participants with mTBI recruited from The Alfred Hospital Level 1 Emergency & Trauma Center and uninjured controls. Follow-up testing was conducted at 7 days. Simoa quantified plasma GFAP, UCH-L1, tau, neurofilament light chain (NfL), interleukin (IL)–6, and IL-1β. Area under the receiver operating characteristic (AUC) analysis assessed classification accuracy for diagnosed mTBI, and logistic regression models identified optimal biomarker combinations. Results Plasma IL-6 (AUC 0.91, 95% CI 0.86–0.96), GFAP (AUC 0.85, 95% CI 0.78–0.93), and UCH-L1 (AUC 0.79, 95% CI 0.70–0.88) best differentiated mTBI (n = 74) from controls (n = 44) acutely (<6 hours), with NfL (AUC 0.81, 95% CI 0.72–0.90) the only marker to have such utility subacutely (7 days). Biomarker performance was similar between sexes and for participants with and without LOC/PTA, with the exception at 7 days, where GFAP and IL-6 retained some utility in female participants (GFAP: AUC 0.71, 95% CI 0.55–0.88; IL-6: AUC 0.71, 95% CI 0.55–0.87) and in those with LOC/PTA (GFAP: AUC 0.73, 95% CI 0.59–0.86; IL-6: AUC 0.71, 95% CI 0.57–0.84). Acute IL-6 (R2 = 0.50, 95% CI 0.34–0.64) outperformed GFAP and UCH-L1 combined (R2 = 0.35, 95% CI 0.17–0.50), with the best acute model featuring GFAP and IL-6 (R2 = 0.54, 95% CI 0.34–0.68). Discussion These findings indicate that adding IL-6 to a panel of brain-specific proteins such as GFAP and UCH-L1 might assist in the acute diagnosis of mTBI in adults younger than 50 years. Multiple markers had high classification accuracy in participants without LOC/PTA. When compared with the best-performing acute markers, subacute measures of plasma NfL resulted in minimal reduction in classification accuracy. Future studies will investigate the optimal time frame over which plasma IL-6 might assist diagnostic decisions and how extracranial trauma affects utility.

17 April 2023 in The Neuroscientist
Verified
Journal Article
Open access
LGLauren P. Giesler
Lauren P. Giesler
RMRichelle Mychasiuk
Richelle Mychasiuk
SSSandy Shultz
Sandy Shultz
SMStuart J. McDonald
Stuart J. McDonald
Traumatic brain injury is a common health problem affecting millions of people each year. BDNF has been investigated in the context of traumatic brain injury due to its crucial role in maintaining brain homeostasis. Val66Met is a functional single-nucleotide polymorphism that results in a valine-to-methionine amino acid substitution at codon 66 in the BDNF prodomain, which ultimately reduces secretion of BDNF. Here, we review experimental animal models as well as clinical studies investigating the role of the Val66Met single-nucleotide polymorphism in traumatic brain injury outcomes, including cognitive function, motor function, neuropsychiatric symptoms, and nociception. We also review studies investigating the role of BDNF on traumatic brain injury pathophysiology as well as circulating BDNF as a biomarker of traumatic brain injury.

19 November 2024 in Sports Medicine
Verified
Journal Article
Open access
PDF file
LELauren J. Evans
Lauren J. Evans
WOWilliam T. O’bRien
William T. O’bRien
GSGershon Spitz
Gershon Spitz
SMSteven Mutimer
Steven Mutimer
BXBecca Xie
Becca Xie
SMStuart J. McDonald
Stuart J. McDonald
Background: Advances in instrumented mouthguards (iMGs) allow for accurate quantification of single high-acceleration head impacts and cumulative head acceleration exposure in collision sports. However, relationships between these measures and risk of brain cell injury remain unclear. Aim: The purpose of this study was to quantify measures of non-concussive head impact exposure and assess their association with blood glial fibrillary acidic protein (GFAP), neurofilament light (NfL) and phosphorylated-tau-181 (p-tau-181) levels in male Australian football players. Methods: A total of 31 athletes underwent in-season (24 h post-match) and post-season (> 5 weeks) blood collections and/or wore HITIQ Nexus A9 iMGs measuring peak linear (PLA) and rotational (PRA) acceleration. Match footage was used to verify and code impacts. Blood GFAP, NfL, and p-tau-181 were quantified using Simoa and natural log transformed for analysis. Associations between post-match biomarkers and within match maximum single impact and cumulative PLA/PRA were assessed with linear mixed models. Results: In-season versus post-season elevations were found for GFAP (mean difference 0.14, 95% CI 0.01–0.26, p = 0.033), NfL (mean difference = 0.21, 95% CI 0.09–0.32, p = 0.001) and p-tau-181 (mean difference = 0.49, 95% CI 0.33–0.65, p < 0.001). Post-match GFAP was associated with maximum single impact PLA (B = 0.003, 95% CI 0.0002–0.005, p = 0.036), cumulative PLA (B = 0.001, 95% CI 0.0002–0.002, p = 0.017), cumulative PRA (B = 0.01, 95% CI 0.002–0.02, p = 0.014), and impact number (B = 0.03, 95% CI 0.003–0.05, p = 0.029) within a single match. Change in NfL levels between two-matches correlated with cumulative PLA (r = 0.80, 95% CI 0.38–0.95, p = 0.005), PRA (r = 0.71, 95% CI 0.19–0.92, p = 0.019) and impact number (r = 0.63, 95% CI 0.05–0.89, p = 0.038). Conclusion: Maximum and cumulative head accelerations in Australian football, measured by iMGs, were associated with elevated blood biomarkers of brain injury, highlighting the potential of both technologies for head impact management in collision sports.

11 March 2025 in Neurology
Verified
Journal Article
Closed access
WOWilliam T. O'BRien
William T. O'BRien
JHJames W. Hickey
James W. Hickey
SMSteven Mutimer
Steven Mutimer
LELauren J. Evans
Lauren J. Evans
BCBlake D. Colman
Blake D. Colman
SMStuart J. McDonald
Stuart J. McDonald
Previous studies on sport-related concussion (SRC) may have measured brain injury blood-based biomarker, glial fibrillary acidic protein (GFAP), either before or after its peak, potentially underestimating the diagnostic value. The primary aim of this study was to evaluate the diagnostic performance of serum GFAP at 24 hours post-SRC. Secondary objectives included assessing whether the timing of sample collection relative to an Australian football match (with or without SRC) affected GFAP levels, evaluating if combining GFAP with symptoms improved discrimination of SRC compared with symptoms alone, and determining the diagnostic utility of serum neurofilament light (NfL) levels at 24 hours post-SRC. In a prospective cohort study, adult male and female Australian football players of the Victorian Amateur Football Association (Melbourne, Australia) with and without SRC had blood sampled around 24 hours postinjury/postmatch. GFAP and NfL levels were quantified using Simoa assays, and area under the curve (AUC) values were calculated for time bins of 16-24 hours, 24-32 hours, and 36-52 hours. Symptom severity at blood collection was assessed using the Sport Concussion Assessment Tool 5 (SCAT). A total of 151 athletes with SRC (median age 22.5 years; 85% male) and 97 controls (median age 24.3 years; 86% male) were sampled at a median of 24.5 hours (interquartile range [IQR] 21.7-28.0; min-max 16-51.5). Time to sample postmatch did not affect GFAP levels in controls; however, higher GFAP levels correlated with shorter time post-SRC (Spearman r = -0.25, 95% CI -0.40 to -0.09). Median GFAP concentrations were 65.9 pg/mL (IQR 49.1-81.3) in controls, and for SRC, 124.6 pg/mL (IQR 86.7-190.7) at 16-24 hours, 94.5 pg/mL (IQR 61.6-163.9) at 24-32 hours, and 59.9 pg/mL (IQR 49.1-94.7) at 36-52 hours. AUC values at 16-24 and 24-32 hours were 0.83 (95% CI 0.76-0.90) and 0.72 (95% CI 0.64-0.80), respectively. Furthermore, combining GFAP with SCAT symptoms at 16-24 hours enhanced discriminatory capability compared with SCAT symptoms alone (AUC increased from 0.91 to 0.97; z = 2.48, p = 0.01). Serum NfL had a limited diagnostic value (AUC ≤0.60). Serum GFAP measured at 16-24 hours following potential or suspected SRC may be a useful objective aid to SRC diagnosis.

16 February 2026 in Sports Medicine - Open
Verified
Journal Article
Open access
LELauren J. Evans
Lauren J. Evans
JHJames W. Hickey
James W. Hickey
JRJonathan Reyes
Jonathan Reyes
BXBecca Xie
Becca Xie
KGKate Gillespie-Jones
Kate Gillespie-Jones
SMStuart J. McDonald
Stuart J. McDonald
The consequences of exposure to head acceleration events (HAEs) in collision sports, including Australian Rules football, are a growing concern. Instrumented mouthguards (iMGs) now enable accurate quantification of HAEs in sport; however, little is known about HAE incidence and mechanisms in Australian Rules football. We aimed to measure HAEs in elite Australian Rules football players, and evaluate the influence of playing position and match event on the incidence and magnitude of HAEs in men and women. iMG data were collected from Australian Football League (AFL) and AFL Women's (AFLW) players in 2023 utilising the HIT-IQ Nexus Gen III iMG, targeting 500 player-matches per sex. Match footage was synchronised with iMG data for video verification and match play coding. Three hundred and eleven players contributed iMG data in the analyses, including 126 men (median matches per player: 3 (interquartile range [IQR: 2-6]) and 185 women (median: 3 [IQR: 1-4]). Men had a higher mean incidence of HAEs ≥ 8 g per match than women (5.7 [95% confidence interval CI: 5.0-6.4] vs. 3.0 [95% CI: 2.8-3.3]), however the incidence was comparable when adjusted for time (3.6/hour [95% CI: 3.2-4.1] vs. 3.1/hour [95% CI: 2.9-3.4]). Men recorded higher maximum single-impact peak linear acceleration (PLA; median 31 g vs. women: median 22 g; p < 0.001) and peak rotational acceleration (PRA; median 3.0 krad/s² vs. women: 2.4 krad/s²; p < 0.001) per match. Conversely, women experienced greater PRA per impact (median 1.4 krad/s² vs. men: 1.2 krad/s²; p < 0.001), while PLA was similar (men: median 14 g, women: median 13 g; p = 0.330). The leading match events resulting in HAEs were marking contests (1.0/hour) in men and contested ball situations (0.8/hour) in women. HAE incidence and magnitude were generally comparable across playing positions, except for men's rucks, who experienced significantly higher incidence of HAEs (6.5/hour) than forwards (3.6/hour), midfielders (3.2/hour), and defenders (2.7/hour). This study highlights differences in HAE incidence, magnitude, and mechanisms by sex, playing position, and match events in elite-level Australian Rules football. These findings provide insight into impact exposure patterns and may inform targeted skill development and policy adjustments to enhance player safety.